XML 20 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Revenues $ 26,460,000 $ 28,563,000 $ 84,069,000 $ 82,715,000
Operating expenses:        
Research and development 65,116,000 62,498,000 183,719,000 179,018,000
General and administrative 16,238,000 14,501,000 46,239,000 47,135,000
Total operating expenses 81,354,000 76,999,000 229,958,000 226,153,000
Loss from operations (54,894,000) (48,436,000) (145,889,000) (143,438,000)
Interest and other income, net 1,769,000 834,000 5,754,000 3,010,000
Loss before income taxes (53,125,000) (47,602,000) (140,135,000) (140,428,000)
Income tax expense 30,000 86,000 170,000 373,000
Net loss (53,155,000) (47,688,000) (140,305,000) (140,801,000)
Net loss attributable to non-controlling interest 0 0 0 (11,000)
Net loss attributable to Sangamo Therapeutics, Inc. stockholders, basic (53,155,000) (47,688,000) (140,305,000) (140,790,000)
Net loss attributable to Sangamo Therapeutics, Inc. stockholders, diluted $ (53,155,000) $ (47,688,000) $ (140,305,000) $ (140,790,000)
Earnings per share, basic (in dollars per share) $ (0.34) $ (0.33) $ (0.93) $ (0.98)
Earnings per share, diluted (in dollars per share) $ (0.34) $ (0.33) $ (0.93) $ (0.98)
Shares used in computing basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares) 158,042 145,399 150,850 144,173
Shares used in computing diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares) 158,042 145,399 150,850 144,173